Dr. Yoon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
200 1st Street SW
Rochester, MN 55905- Is this information wrong?
Summary
- I am a board-certified medical oncologist with a clinical specialization in GI cancers and cancers of unknown primary (CUP) My research focuses on clinical trials of novel agents and translational investigations in gastroesophageal and colorectal cancer and in CUP.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2004 - 2008
Yale-New Haven Medical CenterResidency, Internal Medicine, 2001 - 2004
Yale School of MedicineClass of 2001
Johns Hopkins University Schools of Medicine and Public HealthMHS, Clinical Investigation
Certifications & Licensure
MN State Medical License 2008 - 2024
MD State Medical License 2004 - 2009- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Genes in Predicting Outcome in Patients With Esophageal Cancer Treated With Cisplatin, Radiation Therapy, and Surgery Start of enrollment: 2007 May 11
- A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Start of enrollment: 2011 Apr 01
- Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery Start of enrollment: 2016 Jun 24
- Join now to see all
Publications & Presentations
PubMed
- Advances in Immunotherapy in Esophagogastric Cancer.Khalid Jazieh, Harry Yoon, Mojun Zhu> ;Hematology/oncology Clinics of North America. 2024 Mar 15
- Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an ...Kang, Y., Ryu, M., Di Bartolomeo, M., Chau, I., Yoon, H., Kim, J., Lee, K., Oh, S., Takashima, A., Kryzhanivska, A., Chao, Y., Evesque, L., Schenker, M., McGinn, A., Z...> ;Gastric Cancer. 2024 Mar 1
- Neoadjuvant Immunotherapy in Gastroesophageal Cancer: A Promising Early Signal?Mojun Zhu, Harry H Yoon> ;Journal of Clinical Oncology. 2024 Feb 1
- Join now to see all
Lectures
- From Standardization to Personalized Care: How to Use Molecular Diagnostics to Guide TreatmentASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- Tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- CD3+ and CD8+ tumor-infiltrating lymphocyte (TIL) densities to prognostically stratify DNA mismatch repair-deficient (dMMR) colon cancer patients (pts): NCCTG N0147 (A...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Other
- How Immunotherapy Is Transforming GI Cancer TreatmentHarry Yoon, MD, Op-Med
https://www.doximity.com/articles/01f7f77e-e73f-4d56-9d87-d82c9d8e9faf
UpToDate, Wolters Kluwer Health - 2013-03-12
Authored Content
- How Immunotherapy Is Transforming GI Cancer TreatmentJanuary 2019
Press Mentions
Addition of Tislelizumab to Chemotherapy in First-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell CarcinomaMay 4th, 2023- BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell CarcinomaJune 30th, 2022
- Immunotherapy May Play Role in Treating Nonmetastatic Gastroesophageal CancerMay 16th, 2022
- Join now to see all
Professional Memberships
- Member
- Member
Hospital Affiliations
Mayo Clinic Hospital - RochesterRochester, Minnesota
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
